Dtrm-555

Richter's Transformation

Zhejiang DTRM BiopharmaPhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

57 Active assets in the Richter's Transformation cohort.

Asset / Sponsor	Phase	Rating
Obinutuzumab Christine Ryan	Phase 2	BB
Ibrutinib City of Hope Medical Center	Phase 2	BB
Venetoclax Northwestern University	Phase 2	BB
Pirtobrutinib SWOG Cancer Research Network	Phase 3	BB
Cyclophosphamide SWOG Cancer Research Network	Phase 3	BB

View all 50 →

Same molecule, other indications

Dtrm-555 is also rated in:

B-cell chronic lymphocytic leukemiaDormant

CCC

Indicative ·

53 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

CCC

Indicative ·

51 / 100

diffuse large B-cell lymphomaDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.